Use of Mifepristone in a Hypercortisolemic Patient With End-Stage Renal Disease on Hemodialysis
Albert W. Coo, MD, FACE; Rebecca Ray, FNP-C • 2021 •
© 2024 Corcept Therapeutics, Incorporated
About jeremiah@devisedesigns.com
This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 134 entries already.
Entries by jeremiah@devisedesigns.com
Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid
Greenstein et al. • 2020 • AACR Annual Meeting 2020
Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.
Greenstein et al. • 2020 • Citation: J Clin Oncol 38: 2020 (suppl; abstract #: 3091)
Reversal of Antipsychotic-Induced Weight Gain in Rats with Miricorilant, a Selective Glucocorticoid Receptor (GR) Modulator
Lee et al. • 2020 • 2020 Annual Meeting – American Psychiatric Association (APA)
GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia
Auchus et al. • 2020 • J Endocr Soc. Vol 4, Issue Suppl 1 April-May
Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients
Steffensen et al • 2019 • Horm Metab Res.
The Liver Meeting 2021 (American Association for the Study of Liver Diseases)
Kowdley et al • 2021 •
Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
Pivonello et al • 2021 • Front. Endocrinol., 14 July 2021